C12N2501/65

Methods and compositions for reprogramming cells

The present disclosure relates to methods and compositions for reprogramming cells to a pluripotent state. In particular, it relates to an integration- and feeder cell-free method for reprogramming primary human fibroblast cells to induced pluripotent stem cells (iPSCs).

METHOD FOR PRODUCING PARVALBUMIN-POSITIVE NERVE CELLS, CELL, AND DIFFERENTIATION INDUCER
20220282210 · 2022-09-08 · ·

A production method for parvalbumin-positive nerve cells includes: an expression induction step of inducing expression of Ascl1 gene, Dlx2 gene, and MEF2C gene in a cell, and a differentiation step of culturing the cell after the expression induction to differentiate the cells into parvalbumin-positive nerve cell; a cell into which Ascl1 gene, Dlx2 gene, and MEF2C gene are introduced in an expressible manner; and a differentiation inducer for inducing differentiation of a cell into a parvalbumin-positive nerve cell, including Ascl1 gene, Dlx2 gene, and MEF2C gene, or gene products thereof, as an active ingredient.

METHOD FOR DIAGNOSING AND TREATING ATHEROSCLEROSIS BY USING NANOVESICLE TARGETING SITE OF CHANGE IN BLOOD FLOW
20220290098 · 2022-09-15 · ·

The present invention relates to a method for diagnosing and treating atherosclerosis by using nanovesicle targeting a site of change in blood flow, and more specifically, the present invention provides a stem cell-derived nanovesicle, which is an anti-atherosclerosis diagnosis and treatment platform using a peptide capable of targeting a disturbed blood flow, wherein the nanovesicle provides strong anti-inflammatory and pre-endothelial recovery effects similar to that of a mesenchymal stem cell, and thus it can be used as a new diagnosis and treatment agent capable of preventing the onset of atherosclerosis.

METHODS OF PRODUCING MODIFIED NATURAL KILLER CELLS AND METHODS OF USE

Disclosed herein are method of producing NK cells that include one or more heterologous nucleic acids. The methods include culturing a population of isolated NK cells in the presence of one or more cytokines to produce a population of activated NK cells. The population of activated NK cells are transduced with a viral vector comprising the one or more heterologous nucleic acids, for example by contacting the activated NK cells with viral particles including the viral vector. The resulting transduced NK cells are then cultured in the presence of one or more cytokines, and optionally in the presence of irradiated feeder cells, to produce a population of expanded transduced NK cells. Also disclosed are methods of treating a subject with a disorder (such as a tumor or hyperproliferative disorder) by administering to the subject NK cells produced by the methods described herein.

Materials and methods for modifying the activity of T cells

This disclosure provides miRNA/mRNA pairs that can be used to increase the efficacy of T cells or to down-modulate T cell efficacy and restore equilibrium.

METHODS AND CLINICAL PROTOCOLS AND KITS PERTAINING TO MAKING AND USING THERAPEUTIC COMPOSITIONS FOR CELLULAR TREATMENT
20220220561 · 2022-07-14 ·

Disclosed herein are methods for preparing clinically useable target cells for use in achieving a clinical effect in patients. The protocols disclosed herein have been shown to improve cell yield during collection of target cells, transport of target cells, storage of target cells, and use of target cells. Also disclosed herein are kits and methods for testing patients and preparing clinically useable target cells for use in achieving a clinical effect in patients. The kits and protocols therein improve cell yield during collection of target cells, transport of target cells, storage of target cells, and use of target cells.

METHODS AND CELLULAR STRUCTURES
20220259566 · 2022-08-18 ·

The invention provides methods and compositions for producing a multi-layered cellular structure or blastocyst-like structure from a cell population of reprogrammed somatic cells.

COMPOSITIONS AND METHODS IDENTIFYING AND USING STEM CELL DIFFERENTIATION MARKERS

Provided herein are compositions and methods for identifying and using stem cell regulation factors. For example, in some embodiments, provided herein are compositions and methods for identifying stem cell regulation factors using marker gene expression libraries. Also provided herein are compositions and methods for generating differentiated cells lines and uses of such cell lines.

DIAGNOSTIC AND THERAPEUTIC USES OF COMPOSITIONS COMPRISING PURIFIED, ENRICHED POTENT EXOSOMES CONTAINING DISEASE-BASED AND THERAPY BASED SIGNATURE CARGO

The present disclosure provides a composition containing a purified and enriched population of potent exosomes derived from extracellular vesicles derived from mesenchymal stem cells (MSCs), a method for diagnosing a human subject aged over 50 years with an age-related chronic disease characterized by disease related dysfunction and optimally treating the subject, and a method for reprogramming a donated organ or tissue comprising a fibrotic disposition including treating the donated organ or tissue with a composition comprising purified enriched population of potent exosomes derived from extracellular vesicles derived from MSCs of a normal healthy subject.

mRNA CONSTRUCT FOR PROTEIN EXPRESSION AND USE OF SAME
20220290176 · 2022-09-15 ·

The present invention relates to an mRNA construct, comprising a target protein or peptide coding region and an IRES region downstream of the target protein or peptide coding region, wherein the mRNA construct of the present invention can stably maintain the expression of a target protein for a long time while being stably present in the cell.